Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis

C.D. De Angelis, M.D. Di Maio, A. Crispo, M. Giuliano, F. Schettini, M. Bonotto, L. Gerratana, D. Iacono, M. Cinausero, F. Riccardi, G. Ciancia, M.D. Laurentiis, F. Puglisi, S.D. De Placido, G. Arpino

Research output: Contribution to journalArticlepeer-review

Abstract

The benefit of adding chemotherapy (CT) to adjuvant hormone therapy (HT) in stage IA luminal-like HER2-negative breast cancer (BC) is unclear. We retrospectively evaluated predictive factors and clinical outcome of 1,222 patients from 4 oncologic centers. Three hundred and eighty patients received CT and HT (CT-cohort) and 842 received HT alone (HT-cohort). Disease-free survival (DFS) and overall survival (OS) were evaluated with univariate and multivariate analyses. We also applied the propensity score methodology. Compared with the HT-cohort, patients in the CT-cohort were more likely to be younger, have larger tumors of a higher histological grade that were Ki67-positive, and lower estrogen and progesterone receptor expression. At univariate analysis, a higher histological grade and Ki67 were significantly associated to a lower DFS. At multivariable analysis, only histological grade was predictive of DFS. The CT-cohort had a worse outcome than the HT-cohort in terms of DFS and OS, but differences disappeared when matched according to propensity score. In summary, patients with stage IA luminal-like BC had an excellent prognosis, however relapse and mortality were higher in the CT-cohort than in the HT-cohort. Longer use of adjuvant HT or other therapeutic strategies may be needed to improve outcome. © De Angelis et al.
Original languageEnglish
Pages (from-to)112816-112824
Number of pages9
JournalOncotarget
Volume8
Issue number68
Publication statusPublished - 2017

Keywords

  • Breast cancer
  • Chemotherapy
  • Hormone therapy
  • Luminal-like
  • Propensity score
  • anthracycline derivative
  • antineoplastic hormone agonists and antagonists
  • epidermal growth factor receptor 2
  • estrogen receptor
  • Ki 67 antigen
  • progesterone receptor
  • taxane derivative
  • adjuvant therapy
  • adult
  • adverse outcome
  • age
  • aged
  • Article
  • breast cancer
  • cancer adjuvant therapy
  • cancer center
  • cancer chemotherapy
  • cancer grading
  • cancer hormone therapy
  • cancer mortality
  • cancer prognosis
  • cancer recurrence
  • cancer size
  • cancer staging
  • cancer survival
  • chronic drug administration
  • clinical outcome
  • cohort analysis
  • controlled study
  • diagnostic test accuracy study
  • disease free survival
  • histopathology
  • human
  • human tissue
  • major clinical study
  • multicenter study (topic)
  • outcome assessment
  • overall survival
  • prediction
  • propensity score
  • protein expression
  • reference value

Fingerprint

Dive into the research topics of 'Luminal-like HER2-negative stage IA breast cancer: A multicenter retrospective study on long-term outcome with propensity score analysis'. Together they form a unique fingerprint.

Cite this